Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | GAA | P10253 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13875828 | 0.85 | MAPT (0.45) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL20631 | 0.77 | MAPT (0.61) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL17345212 | 0.77 | MAPT (0.55) | MAPTALDH1A1GAAKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL16209945 | 0.76 | MAPT (0.65) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL20631313 | 0.76 | LMNA (0.61) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL11934591 | 0.74 | F10 (0.43) | MAPTALDH1A1KDM4EKMT2AMEN1 | |
| Dioxane SCHEMBL29124568 | 0.72 | MAPT (0.57) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL13370287 | 0.72 | MAPT (0.50) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL14320289 | 0.72 | PIK3R1 (0.59) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL4386393 | 0.71 | MAPT (0.64) | MAPTALDH1A1GAAKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376449-A1 | PREPARATION PROCESS FOR JAKTINIB DIHYDROCHLORIDE MONOHYDRATE | SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) | 2025-12-11 | — | — | US | disclosed |
| EP-4545523-A1 | PREPARATION PROCESS FOR JAKTINIB DIHYDROCHLORIDE MONOHYDRATE | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023246807-A1 | PREPARATION PROCESS FOR JAKTINIB DIHYDROCHLORIDE MONOHYDRATE | 苏州泽璟生物制药股份有限公司 | 2023-12-28 | — | — | WO | disclosed |
| US-9776973-B2 | Deuterated momelotinib | CONCERT PHARMACEUTICALS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170144977-A1 | DEUTERATED MOMELOTINIB | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9604935-B2 | Deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing the same | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-03-28 | — | — | US | disclosed |
| US-9518027-B2 | Deuterated momelotinib | CONCERT PHARMACEUTICALS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160060227-A1 | DEUTERATED PHENYL AMINO PYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2016-03-03 | — | — | US | disclosed |
| US-20150361051-A1 | DEUTERATED MOMELOTINIB | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060227-A1 | DEUTERATED PHENYL AMINO PYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | JAK1, JAK3, JAK2 | MAPT 1581/4885ALDH1A1 2542/4885GAA 2806/4885 |
| US-20250376449-A1 | PREPARATION PROCESS FOR JAKTINIB DIHYDROCHLORIDE MONOHYDRATE | JAK1, JAK3, JAK2 | MAPT 3284/4885ALDH1A1 1975/4885GAA 1909/4885 |
| US-20170144977-A1 | DEUTERATED MOMELOTINIB | ABL1, JAK1, JAK2 | MAPT 2403/4885ALDH1A1 2175/4885GAA 4016/4885 |
| US-20150361051-A1 | DEUTERATED MOMELOTINIB | ABL1, JAK1, JAK2 | MAPT 2403/4885ALDH1A1 2175/4885GAA 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.